A Phase 3 interventional study of Recombinant Factor VIII (Kovaltry, BAY81-8973) and Recombinant Factor VIII (Kovaltry, BAY81-8973) in Haemophilia A, sponsored by Bayer. Completed at 43 sites in 17 countries. Open to male participants aged 0 Years to 12 Years. Per ClinicalTrials.gov, last updated 2023-12-05.
Sponsored by Bayer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 57 studies in Hemophilia A by Bayer — 3 open to participants now, 6 under way, none of them phase 3. Hemophilia A · Bayer.
Among the 57 studies in Hemophilia A by Bayer, this one is the 4th largest by enrollment of the 31 interventional ones that give a count, is one of 4 that started in 2011, is one of 7 in phase 3, and was the 18th registered.
844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.
Browse Hemophilia A studies →3 of the 57 studies in Hemophilia A by Bayer are open now, in 12 countries. Recruiting first, the newest first:
Bayer · Sites in United States, Brazil, Canada and 8 more countries
Ages 7–12
Bayer · Sites in Korea, Republic of
Ages 12+
Bayer
Ages 18+
By country, each count listing its studies:
Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.
This study: 0 Years to 12 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
57 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 5 · Phase 3 9 · Phase 4 8
First in 2002; this study’s year is marked. 4 started in 2011.
This study's enrollment of 94 is above the median of 30 across 499 interventional studies indexed under Hemophilia A.
Median enrollment 27 across the 31 interventional studies, 67 across the 26 observational. Of the 50 that completed or were terminated, 14 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
3 of the studies in Hemophilia A by Bayer that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03932201BayerEvaluating Effectiveness and Long Term Safety of Damoctocog Alfa Pegol in Patients, Who Have Been Diagnosed With Hemophilia A | 2026-12-31 |
| NCT05643560BayerAn Observational Study Called JOIHA to Learn More About How Well the Treatment With Jivi Works to Prevent Problems With Joints in Adults With Hemophilia A. | 2027-03-31 |
| NCT04461639BayerStudy to Learn More About the Safety of Drug Jivi Over a Long Period of Time in Previously Treated Patients With Hemophilia A (Bleeding Disorder Resulting From a Lack of FVIII) Who Are Receiving Jivi Regularly at Their Treating Doctors to Prevent Bleeding | 2027-03-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 57 studies in Hemophilia A by Bayer, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective was to evaluate the safety and efficacy of the treatment with BAY81-8973 for prophylaxis and treatment of breakthrough bleeds in children with severe hemophilia A.
The secondary objectives were
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Previously treated patients (PTPs) aged below 12 years received BAY81-8973 25-50 IU/kg at least 2x/week for 6 months and at least 50 exposure days (EDs) in main study - Part A. Participants having reached at least 50 EDs in main study - Part A were offered participation in an open label extension study (optional). Participants who transitioned from main study - Part A to the extension study received BAY81-8973, 25-50 IU/kg at least 2x/week for at least 100 cumulative EDs (main study - Part A and extension study).
Biological: Recombinant Factor VIII (Kovaltry, BAY81-8973)
Previously untreated patients (PUPs) or minimally treated patients (MTPs, patients who had no more than 3 exposure days (EDs) with any FVIII product) received BAY81-8973 15-50 IU/kg at least 1x/week for at least 50 EDs or until inhibitor development in main study - Part B. Participants having reached at least 50 EDs in main study - Part B were offered participation in an open label extension study and received BAY81-8973 25-50 IU/kg at least 2x/week for at least 100 cumulative EDs (main study - Part B and extension study); participants who developed an inhibitor in main study - Part B were offered participation in open label extension study and received Immune Tolerance Induction (ITI) treatment with BAY81-8973 until successful eradication of the inhibitor, or until failure, for approximately 18 months.
Biological: Recombinant Factor VIII (Kovaltry, BAY81-8973)
Main study: 25-50 IU/kg at least 2x/week for 6 months and at least 50 EDs, IV infusion; Extension study: 25-50 IU/kg at least 2x/week for at least 100 cumulative EDs (main study - Part A and extension study), IV infusion. Exposure day (ED): An ED is a unit of time (1 day) in which replacement treatment of Hemophilia is given to a patient.
Main study: 15-50 IU/kg at least 1x/week for at least 50 EDs or until inhibitor development, IV infusion; Extension study: For participants having reached at least 50 EDs in main study - Part B: 25-50 IU/kg at least 2x/week for at least 100 cumulative EDs (main study - Part B and extension study), IV infusion. For participants who developed an inhibitor in main study - Part B: up to 200 IU/kg per day or 100 IU/kg twice a day at the discretion of the investigator and coordinating investigator until successful eradication of the inhibitor, or until failure, for up to18 months (treatment beyond 18 months required an agreement with the sponsor and coordinating investigator), IV infusion
Annualized Number of Total Bleeds Within 48 h
Annualized number (mean +/- standard deviation) of total bleeds that occurred within 48 hours after all prophylaxis infusions (Part A: 6 months and at least 50 exposure days \[EDs\]; Part B: at least 50 EDs or until inhibitor development) was summarized and reported. Total bleeds: sum of spontaneous bleeds, trauma bleeds (only treated bleeds were classified as spontaneous or trauma), untreated bleeds and 'other' bleeds ('other' bleeds were infusions with reason given as 'other').
Time frame: Within 48 hours post infusion
Annualized Number of Total Bleeds Within 48 h
Annualized number (median \[inter-quartile range (Q1-Q3)\]) of total bleeds that occurred within 48 hours after all prophylaxis infusions (Part A: 6 months and at least 50 exposure days \[EDs\]; Part B: at least 50 EDs or until inhibitor development) was summarized and reported. Total bleeds: sum of spontaneous bleeds, trauma bleeds (only treated bleeds were classified as spontaneous or trauma), untreated bleeds and 'other' bleeds ('other' bleeds were infusions with reason given as 'other').
Time frame: Within 48 hours post infusion
Annualized Number of Total Bleeds During Prophylaxis Treatment
Annualized number (mean +/- standard deviation) of total bleeds that occurred during prophylaxis treatment was summarized and reported. Total bleeds: sum of spontaneous bleeds, trauma bleeds (only treated bleeds were classified as spontaneous or trauma), untreated bleeds and 'other' bleeds ('other' bleeds were infusions with reason given as 'other').
Time frame: Part A: 6 months and at least 50 exposure days (EDs) (median 73 EDs; median 6 months); Part B: at least 50 EDs or until inhibitor development (median 46 EDs; median 8 months)
Annualized Number of Total Bleeds During Prophylaxis Treatment
Annualized number (median \[inter-quartile range (Q1-Q3)\]) of total bleeds that occurred during prophylaxis treatment was summarized and reported. Total bleeds: sum of spontaneous bleeds, trauma bleeds (only treated bleeds were classified as spontaneous or trauma), untreated bleeds and 'other' bleeds ('other' bleeds were infusions with reason given as 'other').
Time frame: Part A: 6 months and at least 50 exposure days (EDs) (median 73 EDs; median 6 months); Part B: at least 50 EDs or until inhibitor development (median 46 EDs; median 8 months)
Hemostatic Control During Major and Minor Surgeries
For participants who underwent major or minor surgeries during the study, hemostasis during the surgeries was assessed as excellent, good, moderate or poor. Number of surgeries per assessment was summarized and reported.
Time frame: Part A: 6 months and at least 50 exposure days (EDs) (median 73 EDs; median 6 months); Part B: at least 50 EDs or until inhibitor development (median 46 EDs; median 8 months)
Number of Participants With Inhibitor Development in Main Study
Number of participants with confirmed positive FVIII inhibitor titer (≥ 0.6 Bethesda unit \[BU/mL\]) during the main study was summarized and classified as participants developing low titer inhibitor (i.e. ≥ 0.6 to ≤ 5.0 BU/mL) and participants developing high titer inhibitor (i.e. \> 5.0 BU/mL).
Time frame: Part A: 6 months and at least 50 exposure days (EDs) (median 73 EDs; median 6 months); Part B: at least 50 EDs or until inhibitor development (median 46 EDs; median 8 months)
Number of Participants With New Inhibitor Development in Extension Study
Number of participants who had not developed an inhibitor during the main study but developed an inhibitor (confirmed positive FVIII inhibitor titer \[≥ 0.6 BU/mL\]) during the extension study was summarized and classified as participants developing low titer inhibitor (i.e. ≥ 0.6 to ≤ 5.0 BU/mL) and participants developing high titer inhibitor (i.e. \> 5.0 BU/mL).
Time frame: From start of extension study to at least 100 cumulative exposure days (EDs) (median 421 EDs; median 3.8 years)
Factor VIII Recovery Values
Incremental recovery of Factor VIII (FVIII) at 20-30 min after end of infusions was determined and mean recovery values were reported.
Time frame: Part A: 6 months and at least 50 exposure days (EDs) (median 73 EDs; median 6 months); Part B: at least 50 EDs or until inhibitor development (median 46 EDs; median 8 months)
Consumption of Factor VIII in All Infusions
Factor VIII (FVIII) usage/consumption was summarized for all infusions. Consumption per participant's body weight per year was calculated and reported.
Time frame: Part A: 6 months and at least 50 exposure days (EDs) (median 73 EDs; median 6 months); Part B: at least 50 EDs or until inhibitor development (median 46 EDs; median 8 months)
Consumption of FVIII in Infusions for Prophylaxis
Factor VIII (FVIII) usage/consumption was summarized for prophylaxis infusions. Consumption per participant's body weight per year was calculated and reported.
Time frame: Part A: 6 months and at least 50 exposure days (EDs) (median 73 EDs; median 6 months); Part B: at least 50 EDs or until inhibitor development (median 46 EDs; median 8 months)
Consumption of FVIII in Infusions for the Treatment of Bleeds
Factor VIII (FVIII) usage/consumption was summarized for infusions used to treat breakthrough bleeds. Consumption per participant's body weight per year was calculated and reported.
Time frame: Part A: 6 months and at least 50 exposure days (EDs) (median 73 EDs; median 6 months); Part B: at least 50 EDs or until inhibitor development (median 46 EDs; median 8 months)
Number of Infusions Per Bleed
The number of infusions used to treat a bleed was defined as the first infusion to treat the bleed plus all follow-up infusions to treat the same bleed, if any. The mean value of number of infusions for each bleed was calculated and reported.
Time frame: Part A: 6 months and at least 50 exposure days (EDs) (median 73 EDs; median 6 months); Part B: at least 50 EDs or until inhibitor development (median 46 EDs; median 8 months)
Response to Treatment of Bleeds
Participants or caregivers were asked to assess the response to treatment of bleeds as excellent, good, moderate or poor. Percentage of bleeds per assessment was summarized and reported.
Time frame: Part A: 6 months and at least 50 exposure days (EDs) (median 73 EDs; median 6 months); Part B: at least 50 EDs or until inhibitor development (median 46 EDs; median 8 months)
Half-life (t1/2) of BAY81-8973 in Plasma
Half-life (t1/2) of BAY81-8973 in plasma was measured. Geometric mean and percentage geometric coefficient of variation (%CV) were reported.
Time frame: Pre-infusion and until 24 hours post infusion
The study was conducted at multiple centers in 18 countries and consisted of: Part A - between 09-JUN-2011 (FPFV) and 02-JAN-2013 (LPLV); Part B - between 19-SEP-2012 (FPFV) and 09-SEP-2019 (LPLV); Extension study - between 21-DEC-2011 (FPFV) and 27-OCT-2020 (LPLV).
| Milestone | PTPs 0-12 Years | PUPs/MTPs 0-<6 Years |
|---|---|---|
| Started | 51 | 43 |
| Started 0-<6 years | 25 | 43 |
| Started 6-12 years | 26 | 0 |
| Completed | 51 | 22 |
| Not completed | 0 | 21 |
| Withdrew: Protocol violation | 0 | 1 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Inhibitor management | 0 | 17 |
| Withdrew: Withdrawal by subject | 0 | 2 |
| Milestone | PTPs 0-12 Years | PUPs/MTPs 0-<6 Years |
|---|---|---|
| Started | 46 | 36 |
| Completed | 45 | 25 |
| Not completed | 1 | 11 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Iti therapy with marketed product | 0 | 1 |
| Withdrew: Incorrect visit planning | 0 | 1 |
| Withdrew: Family's decision | 0 | 1 |
| Withdrew: Failure of iti therapy | 0 | 3 |
| Withdrew: Long travel | 0 | 1 |
| Withdrew: Diagnosed with von willebrand disease | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Withdrew: Inhibitor management | 0 | 2 |
Annualized number (mean +/- standard deviation) of total bleeds that occurred within 48 hours after all prophylaxis infusions (Part A: 6 months and at least 50 exposure days \[EDs\]; Part B: at least 50 EDs or until inhibitor development) was summarized and reported. Total bleeds: sum of spontaneous bleeds, trauma bleeds (only treated bleeds were classified as spontaneous or trauma), untreated bleeds and 'other' bleeds ('other' bleeds were infusions with reason given as 'other').
| Bleeds | Main Study - Part A: PTPs 0-<6 Years | Main Study - Part A: PTPs 6-12 Years | Main Study - Part B: PUPs/MTPs 0-<6 Years |
|---|---|---|---|
| Annualized Number of Total Bleeds Within 48 h | 2.23 ± 2.77 | 1.86 ± 3.08 | 1.9 ± 3.3 |
Annualized number (median \[inter-quartile range (Q1-Q3)\]) of total bleeds that occurred within 48 hours after all prophylaxis infusions (Part A: 6 months and at least 50 exposure days \[EDs\]; Part B: at least 50 EDs or until inhibitor development) was summarized and reported. Total bleeds: sum of spontaneous bleeds, trauma bleeds (only treated bleeds were classified as spontaneous or trauma), untreated bleeds and 'other' bleeds ('other' bleeds were infusions with reason given as 'other').
| Bleeds | Main Study - Part A: PTPs 0-<6 Years | Main Study - Part A: PTPs 6-12 Years | Main Study - Part B: PUPs/MTPs 0-<6 Years |
|---|---|---|---|
| Annualized Number of Total Bleeds Within 48 h | 1.88 ± 0.00 | 0.00 ± 0.00 | 0.0 ± 0.0 |
Annualized number (mean +/- standard deviation) of total bleeds that occurred during prophylaxis treatment was summarized and reported. Total bleeds: sum of spontaneous bleeds, trauma bleeds (only treated bleeds were classified as spontaneous or trauma), untreated bleeds and 'other' bleeds ('other' bleeds were infusions with reason given as 'other').
| Bleeds | Main Study - Part A: PTPs 0-<6 Years | Main Study - Part A: PTPs 6-12 Years | Main Study - Part B: PUPs/MTPs 0-<6 Years |
|---|---|---|---|
| Annualized Number of Total Bleeds During Prophylaxis Treatment | 4.16 ± 5.02 | 3.37 ± 5.01 | 7.1 ± 8.6 |
Annualized number (median \[inter-quartile range (Q1-Q3)\]) of total bleeds that occurred during prophylaxis treatment was summarized and reported. Total bleeds: sum of spontaneous bleeds, trauma bleeds (only treated bleeds were classified as spontaneous or trauma), untreated bleeds and 'other' bleeds ('other' bleeds were infusions with reason given as 'other').
| Bleeds | Main Study - Part A: PTPs 0-<6 Years | Main Study - Part A: PTPs 6-12 Years | Main Study - Part B: PUPs/MTPs 0-<6 Years |
|---|---|---|---|
| Annualized Number of Total Bleeds During Prophylaxis Treatment | 2.03 ± 0.00 | 0.93 ± 0.00 | 4.7 ± 2.1 |
For participants who underwent major or minor surgeries during the study, hemostasis during the surgeries was assessed as excellent, good, moderate or poor. Number of surgeries per assessment was summarized and reported.
| Surgeries | Main Study - Part A: PTPs 0-<6 Years | Main Study - Part A: PTPs 6-12 Years | Main Study - Part B: PUPs/MTPs 0-<6 Years |
|---|---|---|---|
| Minor surgery — Excellent | 0 | 0 | 3 |
| Minor surgery — Good | 0 | 0 | 1 |
| Minor surgery — Moderate | 0 | 0 | 0 |
| Minor surgery — Poor | 0 | 0 | 0 |
| Minor surgery — Not available | 0 | 0 | 1 |
| Major surgery — Excellent | 0 | 0 | 0 |
| Major surgery — Good | 0 | 1 | 1 |
| Major surgery — Moderate | 0 | 0 | 0 |
| Major surgery — Poor | 0 | 0 | 0 |
| Major surgery — Not available | 0 | 0 | 0 |
Number of participants with confirmed positive FVIII inhibitor titer (≥ 0.6 Bethesda unit \[BU/mL\]) during the main study was summarized and classified as participants developing low titer inhibitor (i.e. ≥ 0.6 to ≤ 5.0 BU/mL) and participants developing high titer inhibitor (i.e. \> 5.0 BU/mL).
| Participants | Main Study - Part A: PTPs 0-<6 Years | Main Study - Part A: PTPs 6-12 Years | Main Study - Part B: PUPs/MTPs 0-<6 Years |
|---|---|---|---|
| Low titer inhibitor | 0 | 0 | 6 |
| High titer inhibitor | 0 | 0 | 17 |
Number of participants who had not developed an inhibitor during the main study but developed an inhibitor (confirmed positive FVIII inhibitor titer \[≥ 0.6 BU/mL\]) during the extension study was summarized and classified as participants developing low titer inhibitor (i.e. ≥ 0.6 to ≤ 5.0 BU/mL) and participants developing high titer inhibitor (i.e. \> 5.0 BU/mL).
| Participants | Extension Study - Former Part A Participants | Extension Study - Former Part B Participants |
|---|---|---|
| Low titer inhibitor (incl. false-positive) | 1 | 0 |
| High titer inhibitor | 0 | 0 |
Incremental recovery of Factor VIII (FVIII) at 20-30 min after end of infusions was determined and mean recovery values were reported.
| International unit (IU)/dL per IU/kg | Main Study - Part A: PTPs 0-<6 Years | Main Study - Part A: PTPs 6-12 Years | Main Study - Part B: PUPs/MTPs 0-<6 Years |
|---|---|---|---|
| Participants without inhibitor | 1.63 ± 0.31 | 1.72 ± 0.46 | 1.76 ± 0.55 |
| Participants with low titer inhibitor | — | — | 0.86 ± 0.56 |
| Participants with high titer inhibitor | — | — | 0.38 ± 0.42 |
Factor VIII (FVIII) usage/consumption was summarized for all infusions. Consumption per participant's body weight per year was calculated and reported.
| international units/kilogram/year | Main Study - Part A: PTPs 0-<6 Years | Main Study - Part A: PTPs 6-12 Years | Main Study - Part B: PUPs/MTPs 0-<6 Years |
|---|---|---|---|
| Consumption of Factor VIII in All Infusions | 5499.1 ± 1996.2 | 4679.1 ± 1688.7 | 2195.8 ± 1903.6 |
Factor VIII (FVIII) usage/consumption was summarized for prophylaxis infusions. Consumption per participant's body weight per year was calculated and reported.
| international units/kilogram/year | Main Study - Part A: PTPs 0-<6 Years | Main Study - Part A: PTPs 6-12 Years | Main Study - Part B: PUPs/MTPs 0-<6 Years |
|---|---|---|---|
| Consumption of FVIII in Infusions for Prophylaxis | 5224.8 ± 1760.2 | 4492.7 ± 1667.6 | 1486.6 ± 963.3 |
Factor VIII (FVIII) usage/consumption was summarized for infusions used to treat breakthrough bleeds. Consumption per participant's body weight per year was calculated and reported.
| international units/kilogram/year | Main Study - Part A: PTPs 0-<6 Years | Main Study - Part A: PTPs 6-12 Years | Main Study - Part B: PUPs/MTPs 0-<6 Years |
|---|---|---|---|
| Consumption of FVIII in Infusions for the Treatment of Bleeds | 457.07 ± 526.87 | 391.64 ± 219.61 | 835.4 ± 1926.4 |
The number of infusions used to treat a bleed was defined as the first infusion to treat the bleed plus all follow-up infusions to treat the same bleed, if any. The mean value of number of infusions for each bleed was calculated and reported.
| Infusions | Main Study - Part A: PTPs 0-<6 Years | Main Study - Part A: PTPs 6-12 Years | Main Study - Part B: PUPs/MTPs 0-<6 Years |
|---|---|---|---|
| Number of Infusions Per Bleed | 1.3 ± 1.8 | 1.4 ± 1.7 | 1.7 ± 8.7 |
Participants or caregivers were asked to assess the response to treatment of bleeds as excellent, good, moderate or poor. Percentage of bleeds per assessment was summarized and reported.
| Bleeds assessed for the response | Main Study - Part A: PTPs 0-<6 Years | Main Study - Part A: PTPs 6-12 Years | Main Study - Part B: PUPs/MTPs 0-<6 Years |
|---|---|---|---|
| Excellent | 20 | 12 | 27 |
| Good | 23 | 18 | 56 |
| Moderate | 0 | 7 | 16 |
| Poor | 1 | 0 | 6 |
Half-life (t1/2) of BAY81-8973 in plasma was measured. Geometric mean and percentage geometric coefficient of variation (%CV) were reported.
| Hours | Main Study - Part A: PTPs 0-<6 Years | Main Study - Part A: PTPs 6-12 Years |
|---|---|---|
| Half-life (t1/2) of BAY81-8973 in Plasma | 13.2 ± 39.7 | 12.1 ± 16.3 |
Collected over Main study - Part A: from the first BAY81-8973 infusion until 3 days after the last infusion (median 6 months); Main study - Part B: from the first BAY81-8973 infusion until 7 days after the last infusion (median 8 months); Extension: from start of extension study until 3 days after the last infusion in extension study (median 3.1 years). Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Main Study - Part A: PTPs 0-<6 Years | 0/25 (0%) | 0/25 (0%) | 16/25 (64%) |
| Main Study - Part A: PTPs 6-12 Years | 0/26 (0%) | 5/26 (19.2%) | 19/26 (73.1%) |
| Main Study - Part B: PUPs/MTPs 0-<6 Years | 0/43 (0%) | 26/43 (60.5%) | 28/43 (65.1%) |
| Extension Study - Former Part A Participants | 0/46 (0%) | 23/46 (50%) | 41/46 (89.1%) |
| Extension Study - Former Part B Participants | 0/36 (0%) | 14/36 (38.9%) | 24/36 (66.7%) |
| Event | Main Study - Part A: PTPs 0-<6 Years | Main Study - Part A: PTPs 6-12 Years | Main Study - Part B: PUPs/MTPs 0-<6 Years | Extension Study - Former Part A Participants | Extension Study - Former Part B Participants |
|---|---|---|---|---|---|
| Anti factor VIII antibody positiveInvestigations | 0/25 | 0/26 | 22/43 | 1/46 | 0/36 |
| Central venous catheterisationSurgical and medical procedures | 0/25 | 0/26 | 1/43 | 2/46 | 4/36 |
| Vascular device infectionInfections and infestations | 0/25 | 0/26 | 0/43 | 2/46 | 3/36 |
| HaemarthrosisMusculoskeletal and connective tissue disorders | 0/25 | 0/26 | 3/43 | 1/46 | 3/36 |
| Blood loss anaemiaBlood and lymphatic system disorders | 0/25 | 1/26 | 0/43 | 0/46 | 2/36 |
| Catheter site haemorrhageGeneral disorders | 0/25 | 0/26 | 0/43 | 0/46 | 2/36 |
| Gastroenteritis rotavirusInfections and infestations | 0/25 | 0/26 | 0/43 | 0/46 | 2/36 |
| Central venous catheter removalSurgical and medical procedures | 0/25 | 0/26 | 0/43 | 1/46 | 2/36 |
| Immune tolerance inductionSurgical and medical procedures | 0/25 | 0/26 | 0/43 | 0/46 | 2/36 |
| Soft tissue haemorrhageMusculoskeletal and connective tissue disorders | 0/25 | 0/26 | 2/43 | 0/46 | 0/36 |
| Event | Main Study - Part A: PTPs 0-<6 Years | Main Study - Part A: PTPs 6-12 Years | Main Study - Part B: PUPs/MTPs 0-<6 Years | Extension Study - Former Part A Participants | Extension Study - Former Part B Participants |
|---|---|---|---|---|---|
| PyrexiaGeneral disorders | 5/25 | 2/26 | 12/43 | 8/46 | 11/36 |
| NasopharyngitisInfections and infestations | 2/25 | 2/26 | 6/43 | 13/46 | 9/36 |
| TonsillitisInfections and infestations | 1/25 | 1/26 | 1/43 | 10/46 | 0/36 |
| Limb injuryInjury, poisoning and procedural complications | 0/25 | 1/26 | 0/43 | 9/46 | 1/36 |
| CoughRespiratory, thoracic and mediastinal disorders | 2/25 | 4/26 | 1/43 | 9/46 | 3/36 |
| HeadacheNervous system disorders | 2/25 | 4/26 | 0/43 | 8/46 | 0/36 |
| VomitingGastrointestinal disorders | 1/25 | 1/26 | 4/43 | 4/46 | 6/36 |
| DiarrhoeaGastrointestinal disorders | 2/25 | 1/26 | 6/43 | 5/46 | 1/36 |
| RhinitisInfections and infestations | 1/25 | 1/26 | 3/43 | 6/46 | 1/36 |
| Upper respiratory tract infectionInfections and infestations | 1/25 | 1/26 | 3/43 | 6/46 | 2/36 |
Safety analysis set (SAF): all participants who entered Study Part A or Part B and received at least one infusion of study medication.
| Age, Continuous(Years) | Main Study - Part A: PTPs 0-<6 Years | Main Study - Part A: PTPs 6-12 Years | Main Study - Part B: PUPs/MTPs 0-<6 Years | Total |
|---|---|---|---|---|
| Mean | 3.8 ± 1.3 | 8.8 ± 1.8 | 1.1 ± 0.8 | 3.9 ± 3.4 |
| Sex: Female, Male(Participants) | Main Study - Part A: PTPs 0-<6 Years | Main Study - Part A: PTPs 6-12 Years | Main Study - Part B: PUPs/MTPs 0-<6 Years | Total |
|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 |
| Male | 25 | 26 | 43 | 94 |
| Ethnicity (NIH/OMB)(Participants) | Main Study - Part A: PTPs 0-<6 Years | Main Study - Part A: PTPs 6-12 Years | Main Study - Part B: PUPs/MTPs 0-<6 Years | Total |
|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 9 | 10 |
| Not Hispanic or Latino | 23 | 25 | 34 | 82 |
| Unknown or Not Reported | 1 | 1 | 0 | 2 |
| Race/Ethnicity, Customized(Participants) | Main Study - Part A: PTPs 0-<6 Years | Main Study - Part A: PTPs 6-12 Years | Main Study - Part B: PUPs/MTPs 0-<6 Years | Total |
|---|---|---|---|---|
| White | 24 | 24 | 37 | 85 |
| Black | 1 | 2 | 1 | 4 |
| American Indian or Alaska native | 0 | 0 | 1 | 1 |
| White, American Indian or Alaska native | 0 | 0 | 1 | 1 |
| Not reported | 0 | 0 | 3 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2011 to primary completion in Sep 2019, 99 months.
Results were first posted in Nov 2020, 1 year 1 month after primary completion.
Of 89 industry-sponsored phase 3 interventional studies under Hemophilia A, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 56. This study's 99 months is above that.
Counting every sponsor, half of 91 studies reached it within 33 months; a quarter within 20 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.